JP2001512103A5 - - Google Patents

Download PDF

Info

Publication number
JP2001512103A5
JP2001512103A5 JP2000505130A JP2000505130A JP2001512103A5 JP 2001512103 A5 JP2001512103 A5 JP 2001512103A5 JP 2000505130 A JP2000505130 A JP 2000505130A JP 2000505130 A JP2000505130 A JP 2000505130A JP 2001512103 A5 JP2001512103 A5 JP 2001512103A5
Authority
JP
Japan
Prior art keywords
alkyl
formula
heteroaryl
compound
alkylcarbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000505130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001512103A (ja
Filing date
Publication date
Priority claimed from GBGB9715894.3A external-priority patent/GB9715894D0/en
Application filed filed Critical
Publication of JP2001512103A publication Critical patent/JP2001512103A/ja
Publication of JP2001512103A5 publication Critical patent/JP2001512103A5/ja
Pending legal-status Critical Current

Links

JP2000505130A 1997-07-29 1998-07-23 第xa因子を阻害する複素環誘導体 Pending JP2001512103A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9715894.3A GB9715894D0 (en) 1997-07-29 1997-07-29 Heterocyclic derivatives
GB9715894.3 1997-07-29
PCT/GB1998/002210 WO1999006371A1 (en) 1997-07-29 1998-07-23 Heterocyclic derivatives which inhibit factor xa

Publications (2)

Publication Number Publication Date
JP2001512103A JP2001512103A (ja) 2001-08-21
JP2001512103A5 true JP2001512103A5 (enExample) 2006-01-05

Family

ID=10816578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000505130A Pending JP2001512103A (ja) 1997-07-29 1998-07-23 第xa因子を阻害する複素環誘導体

Country Status (23)

Country Link
US (2) US6458793B1 (enExample)
EP (2) EP1367054A1 (enExample)
JP (1) JP2001512103A (enExample)
KR (1) KR20010022108A (enExample)
CN (1) CN1265098A (enExample)
AT (1) ATE266007T1 (enExample)
AU (1) AU754747B2 (enExample)
BR (1) BR9811055A (enExample)
CA (1) CA2295945A1 (enExample)
DE (1) DE69823665T2 (enExample)
DK (1) DK1000033T3 (enExample)
ES (1) ES2219894T3 (enExample)
GB (1) GB9715894D0 (enExample)
HU (1) HUP0002528A3 (enExample)
IL (1) IL133516A0 (enExample)
NO (2) NO317419B1 (enExample)
NZ (1) NZ501778A (enExample)
PL (1) PL338355A1 (enExample)
PT (1) PT1000033E (enExample)
RU (1) RU2225404C2 (enExample)
SK (1) SK1272000A3 (enExample)
TR (1) TR200000223T2 (enExample)
WO (1) WO1999006371A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
HUP0101810A3 (en) 1998-01-27 2002-05-28 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors and pharmaceutical compositions containing them
SI1082321T1 (en) * 1998-05-02 2005-06-30 Astrazeneca Ab Heterocyclic derivatives which inhibit factor xa
GB9809349D0 (en) 1998-05-02 1998-07-01 Zeneca Ltd Heterocyclic derivatives
GB9902989D0 (en) * 1999-02-11 1999-03-31 Zeneca Ltd Heterocyclic derivatives
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10134482A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte Isoindole und ihre Verwendung
DE10137163A1 (de) 2001-07-30 2003-02-13 Bayer Ag Substituierte Isoindole und ihre Verwendung
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
EP1569912B1 (en) 2002-12-03 2015-04-29 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
RU2578602C2 (ru) 2005-10-04 2016-03-27 Байер Интеллектуэль Проперти Гмбх Способ получения 5-хлор-n-(5s)-2-оксо-3-[4-(3-оксо-морфолинил)-фенил]-1,3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида в модификации ii (варианты)
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
SMT202400527T1 (it) 2019-07-01 2025-01-14 Tonix Pharma Ltd Anticorpi anti-cd154 e loro usi
CA3207098A1 (en) 2021-01-06 2022-07-14 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies
WO2025248134A1 (en) 2024-05-31 2025-12-04 Tonix Pharma Limited Treatment methods comprising administration of modified cd154 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905526D0 (en) * 1989-03-10 1989-04-19 Fujisawa Pharmaceutical Co N-containing heterocyclic compounds,processes for the preparation thereof and composition comprising the same
US5541330A (en) * 1991-12-10 1996-07-30 Eastman Kodak Company Ion-sensitive compounds
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
UA56197C2 (uk) * 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні

Similar Documents

Publication Publication Date Title
JP2001512103A5 (enExample)
RU2000104829A (ru) Гетероциклические производные, ингибирующие фактор ха
ES2275931T5 (es) Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
AU2002246636B8 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
US20040106605A1 (en) Synergistic methods and compositions for treating cancer
LU90956I2 (fr) Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique
JP2002541215A (ja) ナトリウムチャネル遮断薬組成物およびその使用
JP2001526218A5 (enExample)
RU2002121646A (ru) 1,3-дизамещенные пирролидины в качестве антагонистов альфа-2-адренорецепторов
JP2002520282A5 (enExample)
SK10602003A3 (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
KR900003127A (ko) 강심제
CN1511036B (zh) 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
TW201914591A (zh) 用於治療葡萄膜黑色素瘤之蛋白激酶c抑制劑
JPWO2019169065A5 (enExample)
US7399748B2 (en) Antitumor therapy comprising distamycin derivatives
EP1857442A3 (en) Novel antimycobacterial compounds
US20060135527A1 (en) Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents
US20070191437A1 (en) Continuous Dosing Regimen
KR20040078123A (ko) 에포틸론 및 대사길항물질을 포함하는 조합물
JP5570429B2 (ja) デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法
US20110009335A1 (en) Anticancer Treatments
CA2140781A1 (en) Pharmocologically active .alpha.-¬tertiary-aminomethyl|- benzenemethanol derivatives
US20110281813A1 (en) Method of treating c-kit positive relapsed acute myeloid leukemia
EP1203585B1 (en) Anti-ischemic agent